Psyence Group

"It gives me great pleasure reflecting on the strong progress we are making in executing on Psyence Group’s strategy.

The first phase of setting up our clinical trial in Australia is a significant milestone for our team, especially knowing that the work we do has the potential to significantly benefit patients in a palliative care setting.

We are firmly on track to begin this study in the second half of this year. Together with the progress of our production strategy, we are looking forward to continuing along the path of executing our strategy for the remainder of 2023.”

- Dr. Neil Maresky, Psyence Chief Executive Officer

Nature-derived psilocybin in palliative care is the focus of Psyence Group's Phase IIb clinical trial in Australia. iNGENu CRO the Australian-based, globally focused Contract Research Organization with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry is our partner.

iNGENū is responsible for jointly designing our trial, using a natural drug candidate PEX010, in the setting.

The Australian Federal Government’s Research & Development tax incentive program, which can provide up to a 43.5% rebate on our research and development expenses in Australia, makes it a very cost-effective endeavour.

Australian Trade and Investment Commission (Austrade)
iNGENu CRO



https://psyence.com/2023/03/21/psyence-partners-with-ingenu-for-palliative-care-clinical-trial-in-australia/

We are incredibly proud that Psyence Group is one of the first companies to successfully export pharmaceutical grade into the UK. The UK has the potential to be a leader in psychedelics research and ensuring a supply of pharmaceutical grade psilocybin for future research and clinical trials is important in order for this to happen.

Psyence Group Completes Export Of Pharma Grade Psilocybin Extract To UK Psyence Group Completes Export of Pharma Grade Psilocybin Extract To UK TORONTO, ON/ 20 January 2023 / Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has exported purified pharmaceutical grade psilocybin mushroom extract to its Contr...